MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

FMISO PET Study of Glioblastoma

Not Applicable

Completed

Conditions: Recurrent Glioblastoma

Interventions: Device: FMISO PET
Device: MRI
Drug: Bevacizumab
Drug: CCNU

First Posted Date: 2014-03-03

Last Posted Date: 2021-07-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 11

Registration Number: NCT02076152

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Pain Management in Cancer Patients Using a Mobile Application

Not Applicable

Completed

Conditions: Cancer

Interventions: Other: ePAL Mobile Application

First Posted Date: 2014-02-24

Last Posted Date: 2022-06-27

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 110

Registration Number: NCT02069743

Locations: 🇺🇸
The Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Ensuring Communication in Hospice by Oncology Study (ECHO)

Not Applicable

Completed

Conditions: Head and Neck Cancer
Melanoma
Ovarian Cancer
Cervical Cancer
Uterine Cancer
Sarcoma

Interventions: Behavioral: communication with oncology team

First Posted Date: 2014-02-24

Last Posted Date: 2017-04-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT02069769

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery

Phase 4

Completed

Conditions: Thoracic Spinal Stenosis
Lumbar Spinal Stenosis

Interventions: Drug: Placebo
Drug: Tranexamic Acid

First Posted Date: 2014-02-14

Last Posted Date: 2017-06-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 29

Registration Number: NCT02063035

Locations: 🇺🇸
Massachusetts General Hospital Orthopedic Spine, Boston, Massachusetts, United States

Celiac Disease Genomic Environmental Microbiome and Metabolomic Study

Recruiting

Conditions: Celiac Disease

First Posted Date: 2014-02-12

Last Posted Date: 2025-02-20

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 500

Registration Number: NCT02061306

Locations: 🇺🇸
MassGeneral Hospital for Children, Boston, Massachusetts, United States
🇮🇹
University of Roma La Sapienza, Rome, Italy

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Hepatitis B

Interventions: Drug: Hepatitis B Vaccine
Drug: Alendronate
Drug: Placebo

First Posted Date: 2014-02-07

Last Posted Date: 2016-10-21

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 28

Registration Number: NCT02057263

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Reversal of General Anesthesia With Methylphenidate

Phase 1

Completed

Conditions: Post Operative Cognitive Dysfunction
Emergence From Anesthesia

Interventions: Other: Saline
Drug: Methylphenidate

First Posted Date: 2014-01-31

Last Posted Date: 2019-08-22

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 32

Registration Number: NCT02051452

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women

Not Applicable

Completed

Conditions: Menopause
Hot Flashes
Vasomotor Disturbance

Interventions: Drug: Gabapentin

First Posted Date: 2014-01-20

Last Posted Date: 2019-08-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 32

Registration Number: NCT02040532

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

International Latino Research Partnership

Not Applicable

Completed

Conditions: Substance Use (Drugs, Alcohol)

Interventions: Behavioral: Integrated Intervention for Dual Problems and Early Action

First Posted Date: 2014-01-17

Last Posted Date: 2017-05-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 360

Registration Number: NCT02038855

Locations: 🇺🇸
Cambridge Health Alliance, Somerville, Massachusetts, United States
🇪🇸
Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain
🇪🇸
Universidad Autonoma de Madrid Medical School, Madrid, Spain

Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

Phase 4

Terminated

Conditions: Recurrent Ovarian Cancer
Platinum Sensitive Ovarian Cancer

Interventions: Drug: Carboplatin

First Posted Date: 2014-01-14

Last Posted Date: 2016-12-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 15

Registration Number: NCT02035345

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy